Antigens, antibodies and immunoassays
The Native Antigen Company (NAC) specialises in development and manufacture of native and recombinant viral and bacterial antigens, antibodies and related products. NAC’s products are used by pharmaceutical and IVD manufacturers in vaccine research and serology where proper folding and glycosylation are vital. As well as offering antigens from a rapidly expanding portfolio, NAC undertakes bespoke product development and custom manufacture using its proprietary mammalian cell protein expression system.
Human Coronavirus Product Update
The Native Antigen Company has an extensive range of antigens and antibodies for research into the range of human coronaviruses, including SARS-CoV-2 (better known as the disease COVID-19). If there is a product not current under development by The Native Antigen Company, then please either contact ourselves or The Native Antigen Company directly, as they may be able to develop it for you.
Please follow the links below for the latest information on the currently available human coronavirus products and for information on the human coronavirus products in the development pipeline:
The Native Antigen Company is developing an extensive range of antigens and antibodies for the human coronaviruses, including SARS-CoV-2 (disease, COVID-19).
Human coronovirus development pipeline
To support the investigation of SARS-CoV-2 variants, The Native Antigen Company offers a growing range of mutant Spike antigens. Expressed from our proprietary mammalian expression system, these antigens display full glycosylation and proper folding for use in the development of high-performance assays and other applications.
Human coronavirus mutant spike antigen development pipeline
Currently available human coronavirus products: antigens or antibodies
The following bacterial, protozoan and viral antigens are available:
Antigens: There are now over 60 species of bacterial, protozoan and viral antigens available from NAC and throughout the range, there are often multiple antigens per species. For example, there are 5 CMV antigens available.
The following antibodies are available:
Antibodies: The Native Antigen Company have now developed a high quality range of antibodies that have been carefully tested alongside their antigens, thus providing customers with all of the key components required for immunoassay development and manufacturing. For many of the bacterial, protozoan and viral antibodies, there are multiple antibodies available. For example there are 8 Clostridium difficile antibodies available.
The in addition the extensive range of antigens and antibodies, The Native Antigen Company has introduced a number of new products:
- Virus Like Particles (VLP)
- ELISA Kits – Borrelia burgdorferi IgG, Borrelia burgdorferi IgM, Tick-borne encephalitis Virus IgG, Tick-borne encephalitis Virus IgM, Zika Virus IgG/IgM/IgA, Zika virus IgM and Zika Virus NS1 Capture (in development – Dengue Virus IgG, Dengue Virus IgM and Dengue Virus IgM μ-capture)
- Virus Receptors – MXRA8 Protein (Human) (in development – CLEC4M (Human), DC-Sign (Human), Ephrin B2 (Human), MOG Protein (Human), Neuropilin 2 Protein (Human) and Tyrosine-Protein Kinase Receptor UFO (Human)).
- Veterinary Reagents
- Conjugation and Labelling kits
- Accessory Reagents – including donor sera, isotype controls and secondary antibodies.
- Matched Antibody Pairs